244 filings
Page 6 of 13
CORRESP
b7c 6slvds
17 Apr 23
Correspondence with SEC
12:00am
8-K
bxxblu1pt tuc0uq
12 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
evbbyaz kourq5b
11 Apr 23
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
9:19am
8-K
7zb640lscfd5d02
28 Mar 23
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
5:15pm
8-K
cocp7ik5 0vt13keahqc
24 Mar 23
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
6:08am
8-K
qp132l6x58gr
20 Mar 23
Amendments to Articles of Incorporation or Bylaws
5:14pm
8-K
v8huwdb5tc9spv2
20 Mar 23
Regulation FD Disclosure
6:05am
8-K
sqkpye to
9 Mar 23
Regulation FD Disclosure
5:10pm
D
ky0z0ih
28 Feb 23
$1.20 mm in equity, sold $1.20 mm, 1 investor
6:54pm
8-K
phi 0kzae
28 Feb 23
Entry into a Material Definitive Agreement
5:25pm
8-K
msy7le xnky8xo3
10 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ss1 aj0s3tmn6y9u9
6 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:33am
DEFA14A
btf0jub
24 Jan 23
Additional proxy soliciting materials
6:02am
424B3
l478n02h mzann91mu
23 Jan 23
Prospectus supplement
5:11pm